Oncolytics' Cleverly Cut Subgroup Data Unlikely To Save Reolysin In NSCLC
August appears to be month of bad news for clinical developments in non-small cell lung cancer (NSCLC). Following Bristol-Myers Squibb Co.'s shocking Phase III failure for Opdivo (nivolumab) in first-line NSCLC, Oncolytics Biotech Inc. has also reported disappointing data for its lung cancer drug Reolysin.
You may also be interested in...
The Scrip 100 universe gathers FY 2019 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales. Here In Vivo breaks out the Top 10 in the league table. Which big pharma holds the top spot this year?
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.